ENTIDAD FINANCIADORA: INSTITUTO DE SALUD CARLOS III
INVESTIGADOR PRINCIPAL: JAVIER DE LAS RIVAS SANZ
DOTACIÓN: 167.030,00 euros
TÍTULO: INSTITUTO NACIONAL DE BIOINFORMÁTICA
Over the years the INB has become a clear reference of the Spanish Bioinformatics Community. However, the continuous scientific, technological and societal advances demand to the INB to adapt and extend its activities beyond the initial proposal. The recent incorporation of Spain to ELIXIR has also brought new opportunities and challenges. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. These resources include databases, software tools, training materials, cloud storage and supercomputers. There are 4 use-cases to better articulate the use and interconnection of those resources at different levels. Nowadays, the INB co-leads 4 different work packages at the European H2020 project EXCELERATE which aims to accelerate the implantation of ELIXIR across participating countries. The translation of genomic knowledge into the clinical practice requires coordinated work of various agents, including research and clinical groups, large sequencing infrastructures, analysis platforms and data integration. It is essential to have pilot projects aimed at standardizing circuits and procedures that facilitate the deployment at the Spanish National Health System. Areas in which genomic information can have an immediate impact on clinical practice are in recognizing individuals with genetic risk of developing cancer, in identifying groups of patients who may benefit from therapies based on genomic profiles of tumors and in the identification of the specific variant/s causing a rare disease to a patient. To deliver the right implementation of the Precision Medicine in the Hospitals of the Spanish National Health System, it is also needed to integrate information from biomedical images and electronic health records using a variety of data and text-mining techniques. There are two main objectives which determine the strategic planning for the period 2018 - 2020, and a number of specific ones considering the current leading role in ELIXIR of the INB, and the opportunities and challenges of bringing together a diverse but complementary research and clinical bioinformatics groups.
ESTE PROYECTO ESTÁ COFINANCIADO POR EL FONDO EUROPEO DE DESARROLLO REGIONAL (FEDER). “Una manera de hacer Europa”